These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9226027)

  • 1. OVCA (CA125) second generation: technical aspects and serum levels in controls, patients with liver disease, pregnant women and patients with ovarian disease.
    Cioffi M; Fratta M; Gazzerro P; Di Finizio B; Tucci A; Molinari AM
    Tumori; 1997; 83(2):594-8. PubMed ID: 9226027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value.
    Bonfrer JM; Korse CM; Verstraeten RA; van Kamp GJ; Hart GA; Kenemans P
    Clin Chem; 1997 Mar; 43(3):491-7. PubMed ID: 9068593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical aspects of immunoradiometric thyroglobulin assays.
    Ferrari L; Biancolini D; Seregni E; Aliberti G; Martinetti A; Villano C; Pallotti F; Chiesa C; Bombardieri E
    Tumori; 2003; 89(5):537-9. PubMed ID: 14870780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The second generation CA 125 assays.
    Kenemans P; Verstraeten AA; van Kamp GJ; von Mensdorff-Pouilly S
    Ann Med; 1995 Feb; 27(1):107-13. PubMed ID: 7741988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a second-generation CA125 assay in gynecologic patients.
    Hornstein MD; Goodman HM; Thomas PP; Knapp RC; Harlow BL
    Gynecol Obstet Invest; 1996; 42(3):196-200. PubMed ID: 8938474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoassay of CA125 in ovarian cancer: a comparison of three assays for use in diagnosis and monitoring.
    Fisken J; Leonard RC; Roulston JE
    Dis Markers; 1989; 7(1):61-7. PubMed ID: 2653700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of one first-generation and three second-generation methods for the determination of CA 125.
    Martin MJ; Blockx PP
    Int J Biol Markers; 1996; 11(1):36-9. PubMed ID: 8740640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.
    Davelaar EM; Schutter EM; von Mensdorff-Pouilly S; van Kamp GJ; Verstraeten RA; Kenemans P
    Ann Clin Biochem; 2003 Nov; 40(Pt 6):663-73. PubMed ID: 14629806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of new cancer-associated antigen CA125 II in epithelial ovarian cancers: comparison with CA125.
    Kobayashi H; Tamura M; Satoh T; Terao T
    Clin Biochem; 1993 Jun; 26(3):213-9. PubMed ID: 8330391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter evaluation of the Elecsys CA 125 II assay.
    Hubl W; Chan DW; Van Ingen HE; Miyachi H; Molina R; Filella X; Pitzel L; Ruibal A; Rymer JC; Bagnard G; Domke I
    Anticancer Res; 1999; 19(4A):2727-33. PubMed ID: 10470230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
    Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of second generation CA 125 assays.
    Cosmi EV; Atlante G; Donadio C; Mariani L; Barbati A
    Eur J Obstet Gynecol Reprod Biol; 1995 Jan; 58(1):73-6. PubMed ID: 7758648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new luminescence immunoassay for thyrotropin using coated tubes: evaluation and comparison with immunoradiometric assay.
    Pilo A; Zucchelli GC; Ferdeghini M; Masini S; Calvo S
    J Biolumin Chemilumin; 1989 Jul; 4(1):185-90. PubMed ID: 2801211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant serum CA 125 values in commercial immunoassays.
    van Kamp GJ; Verstraeten AA; Kenemans P
    Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):99-103. PubMed ID: 8365530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ciclesonide ( Byk Gulden).
    Dent G
    Curr Opin Investig Drugs; 2002 Jan; 3(1):78-83. PubMed ID: 12054077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
    Li W; Wang D
    Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of serum mesothelin in malignant and benign ovarian masses.
    Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
    Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of five immunoassay procedures for the ovarian carcinoma-associated antigenic determinant CA 125 in serum.
    Yedema KA; Thomas CM; Segers MF; Doesburg WH; Kenemans P
    Eur J Obstet Gynecol Reprod Biol; 1992 Dec; 47(3):245-52. PubMed ID: 1294413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.